TipRanks
Advertisement
Advertisement

VNDA Stock Latest News

Morning Movers: Boeing jumps after landing $20B Navy contract
The FlyMorning Movers: Boeing jumps after landing $20B Navy contract
2d ago
BA
CAG
Closing Bell Movers: Boeing up on new fighter jet contract
PremiumThe Fly
Closing Bell Movers: Boeing up on new fighter jet contract
2d ago
BA
MU
Vanda Pharmaceuticals reports results from pivotal Phase III study of HETLIOZ
PremiumThe Fly
Vanda Pharmaceuticals reports results from pivotal Phase III study of HETLIOZ
2d ago
VNDA
Vanda Pharmaceuticals up 33% after Phase 3 Hetlioz study met primary endpoint
PremiumThe Fly
Vanda Pharmaceuticals up 33% after Phase 3 Hetlioz study met primary endpoint
2d ago
VNDA
Vanda Pharmaceuticals initiated with an Outperform at Oppenheimer
PremiumThe Fly
Vanda Pharmaceuticals initiated with an Outperform at Oppenheimer
9d ago
VNDA
Vanda awarded Orphan Designation in Europe for treatment of GPP
PremiumThe FlyVanda awarded Orphan Designation in Europe for treatment of GPP
1M ago
VNDA
Vanda Pharmaceuticals price target lowered to $12 from $17 at B. Riley
Premium
The Fly
Vanda Pharmaceuticals price target lowered to $12 from $17 at B. Riley
2M ago
VNDA
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
Premium
The Fly
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
2M ago
VNDA
Vanda Pharmaceuticals Balances Strong Growth With Rising Losses
PremiumCompany Announcements
Vanda Pharmaceuticals Balances Strong Growth With Rising Losses
2M ago
VNDA
Vanda Pharmaceuticals reports Q2 EPS ($1.04) vs. (46c) last year
PremiumThe Fly
Vanda Pharmaceuticals reports Q2 EPS ($1.04) vs. (46c) last year
2M ago
VNDA
Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
PremiumThe Fly
Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
2M ago
VNDA
VNDA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
VNDA Upcoming Earnings Report: What to Expect?
2M ago
VNDA
Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab
PremiumThe FlyVanda announces EMA positive opinion for orphan drug designation of Imsidolimab
3M ago
VNDA
Buy Rating Reaffirmed as Vanda’s Regulatory Catalysts Support Unchanged $21 Price Target
Premium
Ratings
Buy Rating Reaffirmed as Vanda’s Regulatory Catalysts Support Unchanged $21 Price Target
3M ago
VNDA
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
Premium
The Fly
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
3M ago
VNDA
Vanda Shareholders Approve Directors, Auditor and Compensation Plans
PremiumCompany Announcements
Vanda Shareholders Approve Directors, Auditor and Compensation Plans
4M ago
8K
VNDA
Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan
PremiumThe Fly
Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan
4M ago
VNDA
Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
PremiumThe Fly
Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
5M ago
VNDA
Vanda Pharmaceuticals Bets Big on Growth Pipeline
PremiumCompany Announcements
Vanda Pharmaceuticals Bets Big on Growth Pipeline
5M ago
VNDA
Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
PremiumThe FlyVanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
5M ago
VNDA
Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
Premium
The Fly
Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
5M ago
VNDA
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
Premium
The Fly
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
5M ago
VNDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >